Addiction Awareness – Dr. Steve Lynn prt.10
Addiction Awareness – Dr. Steve Lynn prt.10 – Thursday, October 1, 7 pm. Dr. Steve Lynn, board certified in Psychiatry and Addiction Psychiatry, spoke on the evaluation and treatment of individuals with alcohol, drug, or other substance-related disorders, and of those with the diagnosis of co-occurring substance-related disorders. He discussed issues surrounding prescription medicine abuse, adolescent addiction, adult pain medication abuse, kids’ discovery of drug use through the family medicine cabinet, and he fielded questions from those in attendance. Dr. Lynn is a graduate of Wayne State Medical University in Detroit, Michigan, completed his residency at Emory University in Atlanta, and has been in private practice and an attending psychiatrist at Ridgeview Institute and Peachford Hospital for 17 years. Dr. Lynn is certified by the American Society of Addiction Medicine (ASAM), is the Director of Adult Addiction and Impaired Professional Programs at Ridgeview Institute, and served as past President of Ridgeview’s Medical Staff (1995-1996).
Hepatitis C suspect may have infected patients at 4 Detroit-area hospitals …
Filed under: Detroit Drug Treatment
Patients treated at these facilities and who received injectable narcotic medicines should contact the facilities to be tested, according to the Michigan Department of Community Health. So far, there … In New Hampshire, the indictment charges that he …
Read more on Detroit Free Press
Agennix Plunges as Cancer Drug Fails in Trial: Frankfurt Mover
Filed under: Detroit Drug Treatment
Another trial, called Fortis-C, enrolled 100 patients in the U.S. and was testing the drug as an early treatment in lung cancer patients. … Drugs approved for treatment include Roche Holding AG (ROG)'s Avastin and Tarceva and Eli Lilly & Co.'s Alimta.
Read more on Bloomberg
Alzheimer's Drug Fails Its First Big Clinical Trial
Filed under: Detroit Drug Treatment
… July 23, 2012. The most closely watched experimental treatment for Alzheimer's disease proved ineffective in its first large clinical trial, dealing a blow to the field, to a theory about the cause of the disease, and to the three companies behind …
Read more on New York Times